YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
AbbVie ABBV announced that the FDA has granted two Breakthrough Therapy designations (BTDs) to its investigational next-generation antibody-drug conjugate (ADC), telisotuzumab adizutecan (Temab-A; ABBV-400), for two different types of canc…
(RTTNews) - Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botensilimab and balstilimab; and Shoulder In…
(RTTNews) - Pre-market trading is offering an early glimpse into biotech stocks likely to attract investor attention this Wednesday. Significant price moves ahead of the opening bell are being driven by clinical trial updates, public and p…
CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-…
Mettler-Toledo International MTD reported fourth-quarter 2025 adjusted earnings of $13.36 per share, which beat the Zacks Consensus Estimate by 4.67%. The bottom line increased 8% on a year-over-year basis. Net sales of $1.13 billion surpa…
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Re…
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through key anticipated reg…
CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-…
Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index falling 0.8% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
* Actuate Therapeutics (NASDAQ:ACTU [https://seekingalpha.com/symbol/ACTU]) said on Wednesday that it has priced an underwritten public offering [https://seekingalpha.com/pr/20227849-actuate-therapeutics-announces-pricing-of-15_0-million-p…
CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-…
CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-…
Actuate Therapeutics Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU)…
Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Co…
* Actuate Therapeutics (NASDAQ:ACTU [https://seekingalpha.com/symbol/ACTU]) filed a prospectus for resale of 1.33M common shares by existing investors. The offering includes 666,497 outstanding shares and 666,497 shares issuable upon warra…
Investing.com - H.C. Wainwright reiterated its Buy rating and $20.00 price target on Actuate Therapeutics (NASDAQ:ACTU), currently trading at $5.76, following the company’s completion of the Phase 1 portion of its ongoing Phase 1/2 trial w…
- Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients - Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients - Two Additional Patients Had Durable Stable Disease in N…
On June 27, 2025, Bios 2024 Co-Invest, LP, a director and 10% owner of Actuate Therapeutics , Inc. (NASDAQ:ACTU), purchased 71,428 shares of common stock at $7.0, for a total value of $499,996. The purchase comes as the stock has declined…
Director Leslie W. Kreis, along with entities he is affiliated with, reported purchasing 71,428 shares of Actuate Therapeutics , Inc. (NASDAQ:ACTU) common stock at a price of $7.0 per share, for a total transaction value of $499,996. The t…
- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (…
CHICAGO/FORT WORTH - Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage biotech company currently trading at $7.49 per share, has identified seven biomarkers that may help predict which metastatic pancreatic cancer patients could b…
CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-i…
* Actuate Therapeutics (NASDAQ:ACTU [https://seekingalpha.com/symbol/ACTU]) will be added to the Russell 3000 Index, with automatic inclusion in the Russell 2000 Index, effective after the U.S. market close on June 27, as part of the 2025…
Inclusion reflects continued growth and momentum in the company’s mission to transform the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeuti…
[Pancreatitis, pancreatic cancer, Asian doctor with pancreas, gallbladder and bile duct human anatomy model at hospital.] sasirin pamai/iStock via Getty Images Actuate Therapeutics (NASDAQ:ACTU [https://seekingalpha.com/symbol/ACTU]) on Sa…
Actuate's Phase 2 trial shows elraglusib/GnP improves overall survival in mPDAC patients, with a 37% lower death risk. Quiver AI Summary Actuate Therapeutics presented promising results from its Phase 2 trial (Actuate-1801 Part 3B) of elra…
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreat…
Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)Oral presentation at the American Society of Clinical…
- Oral presentation at ASCO to highlight topline Phase 2 data of elraglusibin combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, A…
CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high…
CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-i…